Resources

An epidemiological team investigates a hospital outbreak involving two cohorts. Cohort 1 (n1=120n_1 = 120) presents with acute bloody diarrhea caused by Shiga toxin-producing Escherichia coli (STEC). Cohort 2 (n2=140n_2 = 140) presents with acute viral gastroenteritis caused by Rotavirus. In Cohort 1, 60 patients are empirically treated with ciprofloxacin (a fluoroquinolone), while 60 receive supportive oral rehydration therapy (ORT). In Cohort 1, 15 out of 60 ciprofloxacin-treated patients develop Hemolytic Uremic Syndrome (HUS) due to SOS-response-mediated prophage toxin induction, compared to only 3 out of 60 in the ORT group. In Cohort 2, 70 receive nitazoxanide and 70 receive ORT alone, yielding resolution times of t=31.0 ht = 31.0\text{ h} versus t=56.5 ht = 56.5\text{ h}. (a) For Cohort 1, calculate the relative risk (RR=pcipropORT\text{RR} = \frac{p_{\text{cipro}}}{p_{\text{ORT}}}) of developing HUS following antibiotic administration. (b) For Cohort 2, calculate the percentage reduction in illness duration achieved by nitazoxanide compared to ORT alone. (c) Formulate the clinical guideline explaining why antimicrobial therapy is contraindicated in STEC infections, contrasting it with appropriate supportive care in viral gastroenteritis.

Answer and steps

Final answer

(a) pcipro=1560=0.250p_{\text{cipro}} = \frac{15}{60} = 0.250; pORT=360=0.050p_{\text{ORT}} = \frac{3}{60} = 0.050. Relative risk RR=0.2500.050=5.00\text{RR} = \frac{0.250}{0.050} = 5.00. (b) Percentage reduction: 56.5−31.056.5×100%=25.556.5×100%≈45.1%\frac{56.5 - 31.0}{56.5} \times 100\% = \frac{25.5}{56.5} \times 100\% \approx 45.1\%. (c) Antibiotics such as fluoroquinolones induce a bacterial SOS response in STEC, triggering prophage induction and dramatically escalating Shiga toxin release, which increases the risk of renal microvascular thrombosis (HUS) fivefold. For both uncomplicated STEC and viral rotaviral gastroenteritis, the primary evidence-based standard of care is fluid and electrolyte rehydration therapy, avoiding unnecessary antimicrobial escalation.

Steps

Part (a): Relative Risk Calculation for Hemolytic Uremic Syndrome (HUS)

  1. Calculate the incidence (risk) of HUS in each treatment group:

    • In the ciprofloxacin-treated group (n=60n = 60), 1515 patients developed HUS: pcipro=1560=0.250(25.0%)p_{\text{cipro}} = \frac{15}{60} = 0.250 \quad (25.0\%)
    • In the oral rehydration therapy (ORT) group (n=60n = 60), 33 patients developed HUS: pORT=360=0.050(5.0%)p_{\text{ORT}} = \frac{3}{60} = 0.050 \quad (5.0\%)
  2. Compute the Relative Risk (RR\text{RR}):

    • The relative risk expresses how many times more likely the outcome occurs in the exposed group compared to the unexposed control group: RR=pcipropORT=0.2500.050=5.00\text{RR} = \frac{p_{\text{cipro}}}{p_{\text{ORT}}} = \frac{0.250}{0.050} = 5.00
    • Patients receiving ciprofloxacin had a 5.005.00-fold (or 400%400\%) increased risk of progressing to HUS compared to those managed with supportive ORT.

Part (b): Percentage Reduction in Illness Duration for Viral Gastroenteritis

  1. Identify baseline and intervention resolution times:

    • Baseline duration with supportive care alone (tORTt_{\text{ORT}}) = 56.5 h56.5\text{ h}
    • Duration with nitazoxanide intervention (tnitazoxanidet_{\text{nitazoxanide}}) = 31.0 h31.0\text{ h}
  2. Compute the absolute reduction and percentage decrease:

    • Absolute time saved: Δt=56.5 h−31.0 h=25.5 h\Delta t = 56.5\text{ h} - 31.0\text{ h} = 25.5\text{ h}
    • Percentage reduction relative to the baseline duration: Percentage Reduction=56.5−31.056.5×100%=25.556.5×100%≈45.1%\text{Percentage Reduction} = \frac{56.5 - 31.0}{56.5} \times 100\% = \frac{25.5}{56.5} \times 100\% \approx 45.1\%

Part (c): Clinical Guideline and Biological Mechanism

  • Mechanism of Harm in STEC:

    • Shiga toxin genes (stx1stx_1, stx2stx_2) are carried on lysogenic lambdoid prophages integrated within the E. coli genome.
    • Antibiotics that interfere with bacterial DNA replication—especially fluoroquinolones like ciprofloxacin—induce significant DNA damage. This activates the bacterial SOS response (mediated by the RecA protein).
    • The SOS response promotes the autocatalytic cleavage of the phage repressor, triggering the prophage into the lytic cycle. This leads to massive upregulation of Shiga toxin production, followed by cell lysis and systemic toxin release.
    • Circulating Shiga toxin binds to Gb3\text{Gb}_3 receptors on renal glomerular endothelial cells, leading to microvascular thrombosis, hemolytic anemia, thrombocytopenia, and renal failure (HUS).
  • Clinical Contrast and Core Guideline:

    • STEC Infections: Routine or empiric antimicrobial therapy is strictly contraindicated in suspected or confirmed STEC infections because it directly precipitates life-threatening HUS.
    • Viral Gastroenteritis: Antibiotics provide no pharmacological benefit against viral pathogens such as Rotavirus. While targeted adjunctive therapies (e.g., nitazoxanide) can decrease illness duration, they are non-essential.
    • Cornerstone of Therapy: For both STEC and acute viral enteritis, aggressive oral or intravenous fluid and electrolyte rehydration therapy (supportive care) is the proven, primary standard of care.
  • Common Pitfall: Assuming acute, bloody diarrhea (dysentery) should automatically receive empiric broad-spectrum antibiotics before rapid diagnostic confirmation (such as stool PCR or Shiga toxin immunoassay). Initiating fluoroquinolones before ruling out STEC significantly endangers the patient.

Typical errors

OverviewACEpath Teacher's Diagnosis

01 The student calculates the odds ratio instead of the requested relative risk by comparing odds of HUS rather than probabilities.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    Odds_cipro=1545=13  ⟹  Odds_ORT=357=119  ⟹  RR=15/453/57=15×5745×3=6.33\text{Odds\_cipro} = \frac{15}{45} = \frac{1}{3} \implies \text{Odds\_ORT} = \frac{3}{57} = \frac{1}{19} \implies \text{RR} = \frac{15/45}{3/57} = \frac{15 \times 57}{45 \times 3} = 6.33

    Correct

    pcipro=1560=0.250  ⟹  pORT=360=0.050  ⟹  RR=0.2500.050=5.00p_{\text{cipro}} = \frac{15}{60} = 0.250 \implies p_{\text{ORT}} = \frac{3}{60} = 0.050 \implies \text{RR} = \frac{0.250}{0.050} = 5.00

    You calculated the odds ratio rather than relative risk. Relative risk compares the probability of the outcome occurring in each group (events divided by total cohort size, 1560\frac{15}{60} and 360\frac{3}{60}), whereas you divided events by non-events (1545\frac{15}{45} and 357\frac{3}{57}).

  2. Step 2

    Reduction=56.5−31.056.5×100%=25.556.5×100%=45.1%\text{Reduction} = \frac{56.5 - 31.0}{56.5} \times 100\% = \frac{25.5}{56.5} \times 100\% = 45.1\%

  3. Step 3

    Antibiotics trigger the bacterial SOS response in STEC, inducing prophages that cause increased Shiga toxin production and cell lysis, raising HUS risk, so antibiotics are contraindicated. Viral gastroenteritis is unaffected by antibacterial agents, requiring supportive oral rehydration therapy.

WHAT YOU DID WELL
Compliments from Your Teacher

You accurately formulated the percentage reduction for the viral gastroenteritis cohort.

You clearly explained how antibiotic-induced SOS response and prophage activation increase the risk of hemolytic uremic syndrome in STEC.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Odds Ratio vs. Relative Risk Confusion

no

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You treated risk (probability of an outcome relative to the total group) as odds (ratio of subjects with the outcome to subjects without the outcome), calculating an odds ratio instead of a relative risk.

REASONING PATH
Your ACEpath teacher’s suggested approach
Define Risk (Incidence Probability)
  • Risk (p)=Number of eventsTotal number of exposed individuals=aa+b\text{Risk } (p) = \frac{\text{Number of events}}{\text{Total number of exposed individuals}} = \frac{a}{a + b}

  • Always place the total group size in the denominator when calculating risk.

Calculate Relative Risk
  • RR=pexposedpunexposed=a/(a+b)c/(c+d)\text{RR} = \frac{p_{\text{exposed}}}{p_{\text{unexposed}}} = \frac{a / (a + b)}{c / (c + d)}

  • Divide the risk in the exposed group by the risk in the unexposed group rather than cross-multiplying discordant pairs.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Find the incidence risk in the ciprofloxacin group: pcipro=1560=0.250p_{\text{cipro}} = \frac{15}{60} = 0.250.

  2. Find the incidence risk in the supportive ORT group: pORT=360=0.050p_{\text{ORT}} = \frac{3}{60} = 0.050.

  3. Compute the relative risk: RR=pcipropORT=0.2500.050=5.00\text{RR} = \frac{p_{\text{cipro}}}{p_{\text{ORT}}} = \frac{0.250}{0.050} = 5.00.

Final answer

(a) RR=5.00\text{RR} = 5.00; (b) 45.1%45.1\%; (c) Antibiotics induce the bacterial SOS response, triggering prophage induction and massive Shiga toxin release that increases HUS risk; fluid rehydration is the standard supportive care for both conditions.

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the distinction between probability (events / total) and odds (events / non-events) in clinical trial analysis.

  • Practice identifying whether a clinical question asks for an odds ratio (case-control studies) or relative risk (cohort studies and randomized trials).

OverviewACEpath Teacher's Diagnosis

02 The student uses the treated duration rather than the untreated baseline duration as the denominator when calculating the percentage reduction.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    pcipro=1560=0.25  ⟹  pORT=360=0.05  ⟹  RR=0.250.05=5.0p_{\text{cipro}} = \frac{15}{60} = 0.25 \implies p_{\text{ORT}} = \frac{3}{60} = 0.05 \implies \text{RR} = \frac{0.25}{0.05} = 5.0

  2. Step 2

    Difference=25.5 h\text{Difference} = 25.5\text{ h}

  3. Step 3

    Percentage reduction=25.531.0×100%=82.3%\text{Percentage reduction} = \frac{25.5}{31.0} \times 100\% = 82.3\%

    Correct

    Percentage reduction=25.556.5×100%≈45.1%\text{Percentage reduction} = \frac{25.5}{56.5} \times 100\% \approx 45.1\%

    You divided by the post-treatment duration (31.0 h31.0\text{ h}) instead of the untreated baseline control duration (56.5 h56.5\text{ h}). Percentage reduction must always be calculated relative to the original baseline.

  4. Step 4

    Fluoroquinolones trigger the SOS response in STEC, inducing prophages to increase Shiga toxin synthesis and release, drastically increasing HUS risk and making antibiotics contraindicated. Viral gastroenteritis does not respond to antibiotics, so supportive hydration is standard.

WHAT YOU DID WELL
Compliments from Your Teacher

You calculated both treatment group risks and the relative risk accurately.

You correctly found the absolute difference in hours between the two cohort groups.

You clearly articulated how fluoroquinolones induce the SOS response and escalate Shiga toxin production, making them contraindicated in STEC.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Incorrect Base in Percentage Reduction

No, this is a conceptual confusion between the reference baseline and the final treated value when setting up relative percentage changes.

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You selected the new/treated duration (31.0 h31.0\text{ h}) as the denominator rather than the untreated reference baseline (56.5 h56.5\text{ h}). Percentage change or reduction expresses how much smaller the value became relative to where it started.

REASONING PATH
Your ACEpath teacher’s suggested approach
Identifying the Baseline Denominator
  • Percentage Reduction=Baseline−NewBaseline×100%\text{Percentage Reduction} = \frac{\text{Baseline} - \text{New}}{\text{Baseline}} \times 100\%

  • Always identify the control or starting condition as the reference denominator before calculating percentage reduction.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Identify the baseline untreated duration: tbaseline=56.5 ht_{\text{baseline}} = 56.5\text{ h}.

  2. Divide the absolute difference by the baseline: 25.5 h56.5 h≈0.4513\frac{25.5\text{ h}}{56.5\text{ h}} \approx 0.4513.

  3. Convert to percentage: 0.4513×100%≈45.1%0.4513 \times 100\% \approx 45.1\%.

Final answer

(a) RR=5.00\text{RR} = 5.00; (b) 45.1%45.1\%; (c) Antibiotics induce the bacterial SOS response in STEC, triggering prophage lytic replication and massive Shiga toxin release, which increases HUS risk; fluid/electrolyte rehydration is the evidence-based standard of care.

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the percentage change formula: changeoriginal×100%\frac{\text{change}}{\text{original}} \times 100\%.

  • Label your variables explicitly as 'baseline' and 'intervention' before setting up the ratio in clinical trials.

OverviewACEpath Teacher's Diagnosis

03 The student attributes the contraindication of antibiotics in STEC purely to standard antibacterial resistance rather than SOS-mediated toxin upregulation.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    pcipro=1560=0.25  ⟹  pORT=360=0.05  ⟹  RR=0.250.05=5.0p_{\text{cipro}} = \frac{15}{60} = 0.25 \implies p_{\text{ORT}} = \frac{3}{60} = 0.05 \implies \text{RR} = \frac{0.25}{0.05} = 5.0

  2. Step 2

    Reduction=(56.5−31.0)56.5×100%=25.556.5×100%=45.1%\text{Reduction} = \frac{(56.5 - 31.0)}{56.5} \times 100\% = \frac{25.5}{56.5} \times 100\% = 45.1\%

  3. Step 3

    Antimicrobials are contraindicated in STEC because widespread antibiotic use rapidly selects for resistant bacterial strains that render treatment ineffective, rather than benefiting the patient. Supportive oral rehydration is the mainstay in both STEC and viral diarrhea because antibiotics cannot treat viruses.

    Correct

    Antimicrobial therapy is contraindicated in STEC because DNA-damaging antibiotics (such as ciprofloxacin) trigger the bacterial SOS response, inducing lysogenic prophages to enter the lytic cycle. This causes massive upregulation and release of Shiga toxin, dramatically increasing the risk of microvascular endothelial injury and life-threatening Hemolytic Uremic Syndrome (HUS). Supportive fluid and electrolyte rehydration remains the evidence-based standard of care for both STEC and viral gastroenteritis.

    While selecting for antibiotic resistance is a general epidemiological concern, it is not the reason antibiotics are strictly contraindicated in acute STEC. The direct clinical danger is that antibiotic-induced cellular stress triggers prophage induction and explosive Shiga toxin release, precipitating HUS.

WHAT YOU DID WELL
Compliments from Your Teacher

You accurately set up the proportions and calculated the relative risk of HUS as 5.05.0.

You correctly calculated the percentage reduction in resolution time for viral enteritis as 45.1%45.1\%.

You recognized that fluid rehydration is the cornerstone supportive therapy for acute gastroenteritis.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Pathophysiological Misattribution

no

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You conflated a general public health concern (antimicrobial resistance selection) with the specific, acute pathophysiological mechanism of STEC-induced toxicity (SOS-response-mediated prophage induction and Shiga toxin release).

REASONING PATH
Your ACEpath teacher’s suggested approach
Evaluate Drug-Toxin Interactions
  • In bacterial infections harboring lysogenic prophage-encoded toxins (such as STEC stxstx genes), bactericidal antibiotics activate the RecA-dependent SOS response, leading to prophage excision, lytic replication, and massive toxin surge.

  • Always connect clinical contraindications to the specific molecular pathogen response rather than generic antimicrobial resistance.

Connect Quantitative Findings to Guidelines
  • A fivefold increase in relative risk (RR=5.0\text{RR} = 5.0) points directly to severe acute drug toxicity/harm.

  • Use the calculated clinical outcome (HUS development) to explain why the drug directly harms the host.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Identify the genetic location of Shiga toxin: Genes (stx1,stx2stx_1, stx_2) reside within integrated lambdoid prophages in the E. coli genome.

  2. Analyze the drug effect: Fluoroquinolones cause bacterial DNA breaks, triggering the RecA-mediated bacterial SOS response.

  3. Trace the clinical cascade: Prophage induction leads to bacterial lysis, massive release of Shiga toxin into the bloodstream, binding to renal glomerular Gb3\text{Gb}_3 receptors, and initiation of Hemolytic Uremic Syndrome (HUS).

  4. Synthesize guideline: Antibiotics are contraindicated because they directly induce life-threatening HUS, making supportive fluid management the safe, primary standard of care.

Final answer

(a) RR=5.00\text{RR} = 5.00; (b) Percentage reduction ≈45.1%\approx 45.1\%; (c) Antibiotics are contraindicated in STEC because DNA-damaging agents induce the bacterial SOS response, triggering prophage induction and a massive surge of Shiga toxin release, which precipitates life-threatening Hemolytic Uremic Syndrome (HUS).

NEXT STEPS
Final Takeaways from Your Teacher
  • Review phage lysogeny and the mechanism of RecA activation during the bacterial SOS response.

  • Practice distinguishing between long-term evolutionary drug resistance and immediate pharmacodynamic toxin exacerbation.

  • Work through clinical case scenarios involving toxin-mediated bacterial gastroenteritis (e.g., STEC vs. Clostridioides difficile).

Lock it in

Similar question

01

In a clinical study of 80 patients hospitalized with bacterial pneumonia, 40 receive azithromycin and 40 receive standard amoxicillin. Clostridioides difficile colitis develops in 8 patients in the azithromycin group and 2 patients in the amoxicillin group. Calculate the relative risk (RR) of developing colitis associated with azithromycin.

Answer

pazithro=840=0.20p_{\text{azithro}} = \frac{8}{40} = 0.20; pamox=240=0.05p_{\text{amox}} = \frac{2}{40} = 0.05. Therefore, RR=0.200.05=4.00\text{RR} = \frac{0.20}{0.05} = 4.00.

02

A clinic evaluates an antiviral for Influenza A. The duration of fever in the untreated supportive care group (n=100n = 100) is 72.0 h72.0\text{ h}, while the duration in the antiviral-treated group (n=100n = 100) is 45.0 h45.0\text{ h}. In addition, secondary bacterial pneumonia occurs in 4 treated patients versus 16 untreated patients. Calculate both the percentage reduction in fever duration and the relative risk of pneumonia in the treated cohort.

Answer
  1. Percentage reduction: 72.0−45.072.0×100%=27.072.0×100%=37.5%\frac{72.0 - 45.0}{72.0} \times 100\% = \frac{27.0}{72.0} \times 100\% = 37.5\%.
  2. Relative risk: ptreated=4100=0.04p_{\text{treated}} = \frac{4}{100} = 0.04, puntreated=16100=0.16p_{\text{untreated}} = \frac{16}{100} = 0.16. Thus, RR=0.040.16=0.25\text{RR} = \frac{0.04}{0.16} = 0.25.
03

A cohort study investigates 200 pediatric patients with dysentery: 100 with Shigella sonnei and 100 with STEC. Both groups empirically receive trimethoprim-sulfamethoxazole (TMP-SMX). Among the Shigella cohort, 5 develop prolonged carriage and 95 resolve quickly. Among the STEC cohort, 20 develop HUS, whereas a historical control group of 100 STEC patients treated with supportive hydration alone had only 4 HUS cases. Calculate the relative risk of HUS from TMP-SMX exposure in STEC, and explain why empiric antibiotic selection must depend on rapid organism identification.

Answer
  1. RR=20/1004/100=0.200.04=5.00\text{RR} = \frac{20/100}{4/100} = \frac{0.20}{0.04} = 5.00.
  2. Empiric antibiotics eradicate invasive non-toxigenic pathogens like Shigella to shorten carriage, but in STEC they trigger prophage lytic activation, multiplying toxin production and markedly increasing HUS risk. Diagnostic identification is critical to avoid precipitating life-threatening toxicity.
Loading workspace…